The Quantellect read.As of Nov 19, 2026, 15 active firms cover Pfizer Inc: 6 rate it Buy or better, 8 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. Targets span $25.00 to $35.00, a moderate spread. The average target of $29.14 sits 4% above the current $28.06. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.70 next quarter toward $2.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 active firms
Neutral
Strong Buy00%
Buy640%
Neutral853%
Sell17%
Strong Sell00%
Based on 15 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$29.14
+3.9% upside
Average target across 14 active firms as of Nov 19, 2026 vs $28.06 current
Highest Target$35.00
Average Target$29.14
Lowest Target$25.00
Detailed analyst forecasts for PFE
Showing 1–14 of 14 named analysts shown · 15 active firms in the rating projection
As of Nov 19, 2026, 6 of 15 active firms rate PFE a Buy (8 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PFE EPS & revenue forecast
EPS · NEXT QUARTER
$0.70
Range $0.56 – $0.77 · 8 analysts · -7% YoY
Next period, 8 analysts expect Pfizer Inc to earn $0.70 a share (range $0.56 – $0.77), versus $0.75 a year earlier. Full-year consensus is $3.05, growing to $2.95 the year after.
REVENUE · NEXT QUARTER
$14.1B
Range $13.8B – $14.4B · 8 analysts · -2% YoY
Revenue is expected to reach $14.1B (range $13.8B – $14.4B), -2.3% year-over-year. Full-year consensus is $63.1B, rising to $60.8B next year.
Top analysts covering Pfizer Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PFE.
#1
Jason Gerberry
B of A Securities · Rank #160
Neutral
No targeton PFE
Overall win rate
47%
+ Follow
#2
Vamil Divan
Guggenheim · Rank #211
Buy
$33.00+17.6% to target
Overall win rate
48%
+ Follow
#3
Terence Flynn
Morgan Stanley · Rank #222
Neutral
$26.00-7.3% to target
Overall win rate
36%
+ Follow
#4
CS
Chris Schott
JP Morgan · Rank #287
Neutral
$30.00+6.9% to target
Overall win rate
41%
+ Follow
#5
Derek Archila
Wells Fargo · Rank #481
Neutral
$28.00-0.2% to target
Overall win rate
36%
+ Follow
PFE stock forecast FAQ
What is PFE's average 12-month price target?+
The 14 active firms with a live target average $29.14 for Pfizer Inc over the next 12 months, ranging from a $35.00 high to a $25.00 low, as of Nov 19, 2026.
Is PFE stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 15 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 8 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PFE?+
The Street-high target is $35.00 (Argus Research), and the Street-low is $25.00 (RBC Capital). The average of all 14 active-firm targets is $29.14.
How many active Wall Street firms cover PFE?+
15 active firms have a recognized rating on Pfizer Inc as of Nov 19, 2026, and 14 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PFE?+
Among analysts who currently cover PFE, Jason Gerberry of B of A Securities has the strongest overall Quantellect track record (Rank #160). Their current call is Neutral.
What is Pfizer Inc's projected EPS for next quarter?+
The consensus estimate is $0.70 per share (range $0.56 – $0.77) across 8 analysts. Full-year EPS is projected at $3.05, rising to $2.95 the following year.
How much revenue is Pfizer Inc expected to report next quarter?+
Consensus revenue is $14.1B (range $13.8B – $14.4B). Full-year revenue is projected at $63.1B, growing to $60.8B next year.
Have analysts been upgrading or downgrading PFE lately?+
As of Nov 19, 2026, 6 of 15 active firms rate PFE a Buy (8 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PFE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.